ES2969253T3 - Las opciones sintéticas novedosas hacia la fabricación de (6R,10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6H)-ona - Google Patents
Las opciones sintéticas novedosas hacia la fabricación de (6R,10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6H)-ona Download PDFInfo
- Publication number
- ES2969253T3 ES2969253T3 ES20721374T ES20721374T ES2969253T3 ES 2969253 T3 ES2969253 T3 ES 2969253T3 ES 20721374 T ES20721374 T ES 20721374T ES 20721374 T ES20721374 T ES 20721374T ES 2969253 T3 ES2969253 T3 ES 2969253T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- acid
- formula
- alkyl
- produce
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832614P | 2019-04-11 | 2019-04-11 | |
| PCT/US2020/027655 WO2020210613A1 (en) | 2019-04-11 | 2020-04-10 | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2969253T3 true ES2969253T3 (es) | 2024-05-17 |
Family
ID=70457148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20721374T Active ES2969253T3 (es) | 2019-04-11 | 2020-04-10 | Las opciones sintéticas novedosas hacia la fabricación de (6R,10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6H)-ona |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11788071B2 (en) | 2020-04-10 | 2023-10-17 | Codexis, Inc. | Engineered transaminase polypeptides |
| EP4225757A1 (en) * | 2020-10-12 | 2023-08-16 | Bristol-Myers Squibb Company | A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013033777A2 (pt) * | 2011-03-15 | 2016-09-13 | Abbvie Inc | moduladores de receptor de hormônio nuclear |
| JP6505727B2 (ja) | 2014-01-31 | 2019-04-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (cg-RX-API-DMAC7.html) * | 2014-10-01 | 2018-10-20 | ||
| CN105294496A (zh) | 2015-09-28 | 2016-02-03 | 中山大学 | 一种西酞普兰中间体的制备方法 |
| CN110062757B (zh) | 2017-01-18 | 2022-03-04 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| CN113677682B (zh) | 2019-04-16 | 2023-05-30 | 华润生物医药有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| WO2021013209A1 (zh) | 2019-07-23 | 2021-01-28 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| CA3179679A1 (en) | 2020-04-10 | 2021-10-14 | Codexis, Inc. | Carboxyesterase polypeptides for kinetic resolution |
-
2020
- 2020-04-10 EP EP23169596.6A patent/EP4234555A3/en active Pending
- 2020-04-10 CN CN202080041935.8A patent/CN114375290B/zh active Active
- 2020-04-10 CA CA3132365A patent/CA3132365A1/en active Pending
- 2020-04-10 ES ES20721374T patent/ES2969253T3/es active Active
- 2020-04-10 JP JP2021559890A patent/JP7631218B2/ja active Active
- 2020-04-10 EA EA202192807A patent/EA202192807A1/ru unknown
- 2020-04-10 BR BR112021020368A patent/BR112021020368A2/pt unknown
- 2020-04-10 IL IL287102A patent/IL287102B2/en unknown
- 2020-04-10 MX MX2025014306A patent/MX2025014306A/es unknown
- 2020-04-10 MX MX2021012286A patent/MX2021012286A/es unknown
- 2020-04-10 TW TW109112263A patent/TWI880924B/zh active
- 2020-04-10 KR KR1020267004972A patent/KR20260047658A/ko active Pending
- 2020-04-10 AU AU2020272973A patent/AU2020272973B2/en active Active
- 2020-04-10 WO PCT/US2020/027655 patent/WO2020210613A1/en not_active Ceased
- 2020-04-10 KR KR1020217036807A patent/KR102929951B1/ko active Active
- 2020-04-10 SG SG11202111132WA patent/SG11202111132WA/en unknown
- 2020-04-10 CN CN202411615118.5A patent/CN119775276A/zh active Pending
- 2020-04-10 US US17/602,059 patent/US12378246B2/en active Active
- 2020-04-10 EP EP20721374.5A patent/EP3953334B1/en active Active
- 2020-04-13 AR ARP200101024A patent/AR118649A1/es unknown
-
2025
- 2025-02-05 JP JP2025017468A patent/JP7885383B2/ja active Active
- 2025-06-18 US US19/242,506 patent/US20260092066A1/en active Pending
-
2026
- 2026-02-25 AU AU2026201396A patent/AU2026201396A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102473601B1 (ko) | Ep4 길항약과 면역 체크 포인트 저해약을 포함하여 이루어진 조합 | |
| EP2855452B1 (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment of thromboembolic diseases | |
| ES2733096T3 (es) | Intermediarios para la síntesis de ligadores P1 cíclicos como inhibidores del factor XIA | |
| KR100652535B1 (ko) | Impdh 효소의 억제제 | |
| AU2026201396A1 (en) | Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one | |
| ZA200601055B (en) | Regioselective synthesis of CCI-779 | |
| WO1996040686A1 (en) | Heterocyclic substituted cyclopentane compounds | |
| EP3676270A1 (en) | Macrocyclic compounds that inhibit mcl-1 protein | |
| JP2022539570A (ja) | ニューロキニン-1アンタゴニスト | |
| JP2025156455A (ja) | チアゾロ[5,4-b]ピリジンMALT-1阻害剤 | |
| CA3195024A1 (en) | A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one | |
| EA050867B1 (ru) | СПОСОБ ПОЛУЧЕНИЯ (6R,10S)-10-{4-[5-ХЛОРО-2-(4-ХЛОРО-1Н-1,2,3-ТРИАЗОЛ-1-ИЛ)ФЕНИЛ]-6-ОКСО-1(6Н)-ПИРИМИДИНИЛ}-1-(ДИФТОРОМЕТИЛ)-6-МЕТИЛ-1,4,7,8,9,10-ГЕКСАГИДРО-11,15-(МЕТЕНО)ПИРАЗОЛО[4,3-b][1,7]ДИАЗАЦИКЛОТЕТРАДЕЦИН-5(6Н)-ОНА | |
| EP2163553B1 (en) | Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof | |
| CS354591A3 (en) | Aminodiole derivatives, process of their preparation and their use | |
| EP3957638A1 (en) | Macrocyclic derivatives acting as xia factor inhibitor | |
| CN104530029A (zh) | 作为Xa因子抑制剂的杂环化合物及其使用方法和用途 | |
| HK40124045A (en) | Novel synthetic options towards the manufacture of a compound | |
| HK1138580B (en) | Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof |